ABSTRACT We have examined the inhibitory effect of atropine and sodium cromoglycate (SCG) on the bronchial response to sulphur dioxide (SO2) in groups of normal and asthmatic subjects. Eleven normal subjects were premedicated with propranolol (100 mg orally) one laboratory workers (table 1) in all of whom we studied the blocking effects of atropine and sodium cromoglycate. In four of these subjects we studied the reproducibility of the SO2 response in addition.
atropine methonitrate (0 2%), or SCG (1 %). Fifteen minutes later sGaw was remeasured and the subject then breathed SO2 (8 ppm) for three minutes through the mouth. Specific airways conductance was measured for the duration of the subsequent response. Intervals between experiments on any one subject were one week or more. After control SO2 inhalation sGaw decreased in all subjects (mean 34 + 17 (SD) %). Atropine and SCG significantly inhibited the SO2 response (p < 0 01 for both). After atropine the mean decrease in sGaw was 13 + 24 %; after SCG 16 + 12 % (range -3-+ 55 %). With atropine the degree of inhibition was inversely related to the subject's responsiveness to the control SO2 inhalation (r = -0 75; p < 0 01). In four asthmatics (without beta-blockade and with lower SO2 exposure) atropine did not inhibit the SO2 response; SCG had a similar effect to that seen in normal subjects. Therefore, vagal efferent mechanisms are involved in the bronchial response to SO2 in normal subjects, but the lack of inhibition caused by atropine in hyperreactive normal and asthmatic subjects suggests that vagal mechanisms are not important in the causation of hyperreactivity to SO2. The mechanism of inhibition with SCG is unknown.
Inhalation of low concentrations (5-15 parts per million (ppm) ) of SO2 increases airway resistance in man.' 2 In normal subjects Nadel et al3 found that the rise in airway resistance was prevented by atropine, but in asthmatics Booij-Noord et at2 could not block the S02 response with an anticholinergic agent, or by ganglion blockade. De Vries et at4 showed that the response to S02 of asthmatics was partially inhibited by sodium cromoglycate.
In this study we have examined the effect of atropine and sodium cromoglycate on the bronchial response to SO2 of normal and asthmatic subjects. We have also examined the reproducibility of the response to SO2 at various time intervals. The results of this study have been presented previously in abstract.5
Methods
The normal subjects were 11 healthy physicians and laboratory workers (table 1) in all of whom we studied the blocking effects of atropine and sodium cromoglycate. In four of these subjects we studied the reproducibility of the SO2 response in addition.
We also examined the blocking effect of atropine and sodium cromoglycate in four asthmatics (table 1) . Three of these were atopic with symptoms beginning in childhood, positive family history and positive cutaneous sensitivity tests to several allergens. The other asthmatic developed symptoms of asthma in his fifth decade, had no known allergies, negative family history, and negative skin tests. Symptoms in the atopic subjects were mild; one subject was asymptomatic apart from exercise-induced wheezing, while the other two had intermittent mild wheezing attacks, usually at night, relieved by inhaled salbutamol, and they were also taking sodium cromoglycate regularly. Both salbutamol and sodium cromoglycate were discontinued 24 hours before the experiments. The non-allergic asthmatic had severe symptoms requiring continuous treatment with prednisolone and corticotrophin, and intermittent salbutamol inhalation. Although this subject's drugs could not be dis- continued, he did not receive salbutamol over the 12 hours before each experiment. Two of the asthmatics were physicians; all had previously attended the laboratory on several occasions for similar testing of their bronchial reactivity.
In addition to the study with atropine and sodium cromoglycate, one of the atopic asthmatics was a subject in the studies of the reproducibility of the S02 response.
All the subjects were volunteers who were fully informed about the procedure and its experimental nature.
Normal subjects received propranolol (100 mg) orally one hour before inhalation of S02.6 We measured airway resistance (Raw) and thoracic gas volume (Vtg) using a constant volume body plethysmograph.7 Vtg is the lung volume at which the subject performs the panting manoeuvre which is known to be above FRC. In general we have presented our results in terms of "specific" airways conductance, sGaw (= (Raw x Vtg)-'), the conductance per unit lung volume. To establish a baseline, we made duplicate measurements at minute intervals for five minutes, after which the subjects inhaled an aerosol from a Wright nebuliser powered by compressed air at 10 ]/min for five minutes (average volume nebulised = 2-0 ml). In the first experiment on each subject the aerosol was of distilled water, but in subsequent experiments we used aerosols of atropine methonitrate (0-2 %) and sodium cromoglycate (1 %) in random order. Two subjects received sodium cromoglycate in the form of a powder (20 mg) using the standard "spinhaler". The subject re-entered the plethysmograph 10 minutes after aerosol inhalation and we made duplicate measurements of Raw and Vtg at minute intervals for 10 minutes.
The subject then sat outside the plethysmograph and breathed SO2 from a mixing chamber at a concentration of 8 ± 0 5 ppm. The mixing chamber was fed with SO2 (in air) and air from cylinders, both at accurately known flow rates. The diluted gas (20 1/min) left the mixing chamber through a long wide-bore tube (volume two litres) to be discharged outside the laboratory. The subject breathed via a two-way respiratory valve from a side port of this tube close to the mixing chamber. This arrangement allowed the subject to take a breath of up to two litres at correct concentration without appreciably altering the pressure in the system. The subject's expired gas was also discharged outside the laboratory.
Normal subjects breathed the mixture for three minutes; three of the asthmatics for one minute; one atopic asthmatic who was known to be highly reactive to a variety of stimuli was given 4 ppm for 30 seconds only. The subject then re-entered the plethysmograph and we made the first measurements of Raw and Vtg within 60 seconds of the end of S02 inhalation. We used an identical procedure for the blocking experiments with atropine and sodium cromoglycate.
To assess the size of the response to SO2 we have compared the mean of the last five consecutive conductance (sGaw) in all subjects. The mean rise of Raw was 56-8 ± 461 % and the mean fall of sGaw was 34-4 ± 17-3 %. Changes in Vtg were less consistent, but the mean effect was a 4 9 ± 11 -2% rise. The lowest value of sGaw was usually during the first two minutes after exposure.
Although all the subjects noticed the unpleasant taste of SO2 and had a feeling of irritation in the throat, symptoms related to broncho-constriction were mild or absent in nine subjects. Two subjects with the greatest conductance changes were moderately distressed by chest tightness with wheezing for five minutes after inhalation.
Asthmatics (fig 2)
Raw and Vtg rose by 77 5 + 58-9 % and 9-6 + 9.7 % respectively after SO2 inhalation. The mean fall of sGaw was 44 5 ± 225%. All subjects noticed mild chest tightness. Vtg by 9 7 ± 18 2% (p > 0 2); and sGaw increased by 58-2 ± 51l8 % (p < 0-001).
After SO2 inhalation the mean fall of sGaw from the post-atropine control level was 12 7 + 24 0% (p < 005). Three subjects bronchodilated in response to S02 and in one subject there was no change (fig 3) . In all subjects the percentage fall in sGaw after SO2 was less than after the control exposure (p < 0 001). The degree of protection conferred by atropine was inversely related (r = -075; p < 0 01) to the size of the subject's response to S02, so that while small responses were completely abolished by atropine, there was little blockade of the largest responses (figs 3 and 4). There was no significant relationship between the degree of bronchodilatation caused by atropine and the degree of protection.
Asthmatics (figs 2, 3, 5)
After atropine inhalation Raw fell by 31 + 11 %;
Vtg rose by 15 ± 23%; sGaw rose by 41 ± 36%. There was, however, minimal blockade of the bronchial response to SO2 seen in one subject only.
In three subjects the fall in sGaw as a percentage of the post-atropine control level was greater than without atropine (fig 3) . In two subjects a lower absolute level of sGaw was reached after SO2 in the Basehne specific conductance (cmH20 x s)
Fig 5 Effect of atropine on baseline sGaw and on response to SO2 in normal and asthmatic subjects (before atropine = 0; after atropine = 0). After atropine baseline sGaw is increased in all but one subject and the SO2 response is usually diminished, as shown by the closer grouping ofpost-atropine points around the line of identity (
). In several subjects, however, the effect of atropine is to increase sGaw parallel to the line of identity. The absolute magnitude of their response is thus unaltered, but it is smaller when represented as a percentage of the higher baseline sGaw. In five subjects (four asthmatic; one normal) atropine displaces the points away from the line of identity and in three of these the absolute sGaw after SO2 is lower in the atropinised state. atropinised state despite the higher level of the control readings after atropine ( fig 5) .
EFFECT OF SODIUM CROMOGLYCATE (TABLE 2) Normal subjects (figs I and 6) Inhalation of sodium cromoglycate had no significant effect on Raw or sGaw. After SO2 there was a significant rise in Raw (mean 15-5 ± 23-6 %) and fall of sGaw (mean 16 1 + 11-9%) (p < 0 001) from baseline levels, though in all subjects but one the changes were smaller than with the control exposure.
Asthmatics (fig 6)
There was a fall in sGaw (mean 24-0 ± 20-9 %) after sodium cromoglycate inhalation because of a rise in Raw (mean 39-6 ± 58l1%). After SO2 the change in sGaw was less than half that of the control exposure (mean fall 15 2 ± 15.4%). In two atopic subjects, the response was effectively abolished in the presence of sodium cromoglycate while in one subject the response was considerably diminished. The nonallergic subject showed no protection from the drug. The effect of sodium cromoglycate on asthmatics, therefore, did not reach statistical significance.
REPETITION OF THE SO2 RESPONSE (FIG 7)
At four hours the S02 response decreased from a control fall of sGaw of 35-5 ± 11-4% to a fall of 20-6 ± 15 5 % (n = 5). The four-hour response was smaller in each subject. Tachyphyllaxis was hardly detec- In the normal subjects we found an inverse relation-Mechanisms of sulphur dioxide-induced bronchoconstriction in normal and asthmatic man ship between bronchial reactivity to SO2 and the degree to which the response could be blocked with atropine: the largest reactions were least blocked. The asthmatic subjects were more reactive than the most reactive normal subjects and in this group atropine had the least protective effect. Thus, no cholinergic reflex mechanism appears to be involved in the bronchial response to S02 in these asthmatics.
It remains possible that a non-cholinergic reflex pathway may be involved. For instance, the efferent limb of such a reflex could involve purinergic or alphaadrenergic nerves and therefore be unaffected by atropine.
The delivery of atropine to the airways was probably similar in the two groups since their degrees of bronchodilatation were similar. Thus, after atropine inhalation the conductance in the asthmatics increased by 41 %, and in the normal subjects by 52 %.
We Tachyphyllaxis of the bronchial response to SO2 was first described by Frank et all6 who showed that when an SO2 challenge was repeated after 15 minutes, the second response was smaller. This effect was not seen when the interval between responses was one month or more. We have shown attenuation of the response after four hours which was much less at 24 hours. The mechanism of this effect is not known.
